4 articles with Universal Cells
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Astellas will pay Adaptimmune an upfront payment, research funding, development and commercial milestones, and royalties on net sales on co-commercialized products
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require HLA matching.
Universal Cells will get $9 million upfront and is eligible to regulatory milestones payments of up to $115 million, as well as royalties.